CSIMarket


Perspective Therapeutics Inc   (CATX)
Other Ticker:  
 


 

Perspective Therapeutics Inc

CATX's Financial Statements and Analysis



Perspective Therapeutics Inc increased forth quarter of 2023 net loss per share of $-0.09 compare to net loss per share of $-0.03 recorded in the same quarter a year ago a decrease compare to $-0.04 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.09 $  -1,966 Mill
$-0.06     $-1,967M    



Perspective Therapeutics Inc 's Revenue fell by -139138.19 % in forth quarter of 2023 (Dec 31 2023) year on year, to $-1,966 million and declined by sequentially.


Perspective Therapeutics Inc is

More on CATX's Income Statement



Perspective Therapeutics Inc 's net income of $24.484 million in the forth quarter of 2023 increased from net loss of $-4.068 million I. Quarter a year ago.

Sequentially Company turn into Profitability from net loss of $-10.356 million recorded in previous quarter.

More on CATX's Growth

Perspective Therapeutics Inc Inventories
In Dec 31 2023 company's net cash and cash equivalents decreased by $-32 million


Perspective Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Perspective Therapeutics Inc payed $ -0.02 cash per share, on a free-cash flow basis .

Book value fell by -21.94 % sequentially to $0.27 per share, -46.07% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.00 per share from $ 0.08.

Company repurchased 6.98 million shares or 2.49 % in Dec 31 2023.


More on CATX's Dividends

 Market Capitalization (Millions) 410
 Shares Outstanding (Millions) 274
 Total Debt (Millions $) 2
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 3
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Perspective Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Perspective Therapeutics Inc had negative $ -0.02 cash flow per share, on a free-cash flow basis .

Book value fell by -21.94 % sequentially to $0.27 per share, -46.07% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.00 per share from $ 0.08.

Company repurchased 6.98 million shares or 2.49 % in Dec 31 2023.


More on CATX's Balance Sheets

 Market Capitalization (Millions) 410
 Shares Outstanding (Millions) 274
 Total Debt (Millions $) 2
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 3
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Perspective Therapeutics Inc Earnings

Perspective Therapeutics Inc Regains Strong Financial Footing in Q1 2023, While Revenue Moderately Retreats

According to the latest financial news, Perspective Therapeutics Inc has achieved a significant improvement in its financial performance in the first quarter of 2023. The company has reported a balanced book of $0.00 per share, which is a substantial growth compared to the previous year's $-0.01 per share, and the previous reporting period's $-0.03 per share. This result is a promising sign for the company, indicating its resilience and sustainability among the competition in the market.
However, the company's revenue for the January to March 31, 2023 period has dropped by -26.74% to $2.06 million from the same period a year ago, where it had been $2.82 million. Despite the decline in revenue, the compan...